Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713432 | 0.91 | GLA (0.47) | PTGDR2GLAPTGDRAPEX1KDM4E | |
| SCHEMBL4713223 | 0.89 | GLA (0.49) | PTGDR2GLACYP2C9APEX1KDM4E | |
| SCHEMBL4715037 | 0.89 | GLA (0.51) | PTGDR2GLACYP2C9APEX1KDM4E | |
| SCHEMBL4712989 | 0.88 | GLA (0.46) | PTGDR2GLACYP2C9APEX1KDM4E | |
| SCHEMBL4789333 | 0.88 | GLA (0.50) | PTGDR2GLAAPEX1KDM4E | |
| SCHEMBL4716910 | 0.86 | GLA (0.48) | PTGDR2GLACYP2C9APEX1KDM4E | |
| SCHEMBL2802492 | 0.85 | PTGDR2 (0.42) | PTGDR2PTGDRCYP1A2CYP3A4CYP2C8 | |
| SCHEMBL4714008 | 0.84 | GLA (0.51) | PTGDR2GLAAPEX1KDM4E | |
| SCHEMBL2803782 | 0.83 | CYP2C9 (0.54) | PTGDR2GLACYP2C9APEX1KDM4E | |
| SCHEMBL4715837 | 0.83 | GLA (0.48) | PTGDR2GLAAPEX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008048866-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048866-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | PTGDR2 714/4885GLA 140/4885PTGDR 808/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | PTGDR2 263/4885GLA 205/4885PTGDR 380/4885 |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GPR6, CNR1, NR3C1 | PTGDR2 589/4885GLA 4292/4885PTGDR 293/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | PTGDR2 483/4885GLA 166/4885PTGDR 329/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | PTGDR2 113/4885GLA 639/4885PTGDR 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.